This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barth, A. Articles by Morton, D. L. Search for Related Content PubMed PubMed Citation Articles by Barth, A. Articles by Morton, D. L.

Polyvalent Melanoma Cell Vaccine Induces Delayed-Type Hypersensitivity and in Vitro Cellular Immune Response¹

John Wayne Cancer Institute at Saint John's Hospital and Health Center, Santa Monica, California 90404

Patients with melanoma metastatic to distant sites or at high risk for recurrent melanoma have been treated with a polyvalent melanoma cell vaccine (MCV) in phase II protocols. We assessed in vivo and in vitro cell-mediated responses to MCV in 163 patients who had undergone surgical resection of American Joint Committee on Cancer stage III melanoma. During the first 4 months of vaccine immunotherapy, 135 patients (83%) responded by developing a positive delayed-type hypersensitivity reaction 6 mm to MCV. In a mixed lymphocyte tumor cell reaction using peripheral blood lymphocytes, 35 of 42 patients (83%) showed a recall proliferative response to one or more of the three cell lines of MCV. There was a significant correlation between delayed-type hypersensitivity reaction and mixed lymphocyte tumor cell reaction (P = 0.013). After 4 months of MCV therapy, 8 of 11 patients had an increased mixed lymphocyte tumor cell reaction to autologous melanoma cells. During the first 4 months of vaccine therapy, 16 of 33 patients developed more than a 50% increase in cytotoxic T-cell activity against one of the cell lines of MCV. Overall survival was significantly prolonged in patients with a positive delayed-type hypersensitivity reaction (P = 0.0054) and/or increased cytotoxic T-cell activity (P = 0.02). These findings suggest that MCV induces specific T-cell responses which are correlated with clinical course; the data also suggest that some of these responses are directed against autologous melanomas and may play a major role in controlling the progression of melanoma.

¹ Supported by Grant CA 12582, National Cancer Institute, Bethesda, MD; the Cancer League of Bern, Switzerland; and the Joyce and Ben Eisenberg Foundation.

² To whom requests for reprints should be addressed, at John Wayne Cancer Institute, 2200 Santa Monica Blvd., Santa Monica, CA 90404.

Received 2/21/94. Accepted 5/18/94.

This article has been cited by other articles:

				J. Poust Targeting metastatic melanoma Am. J. Health Syst. Pharm., December 15, 2008; 65(24_Supplement_9): S9 - S15. [Abstract] [Full Text] [PDF]

				G. J. Ullenhag, J.-E. Frodin, M. Jeddi-Tehrani, K. Strigard, E. Eriksson, A. Samanci, A. Choudhury, B. Nilsson, E. D. Rossmann, S. Mosolits, et al. Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor Clin. Cancer Res., May 15, 2004; 10(10): 3273 - 3281. [Abstract] [Full Text] [PDF]

				J. Nemunaitis, D. Sterman, D. Jablons, J. W. Smith II, B. Fox, P. Maples, S. Hamilton, F. Borellini, A. Lin, S. Morali, et al. Granulocyte-Macrophage Colony-Stimulating Factor Gene-Modified Autologous Tumor Vaccines in Non-Small-Cell Lung Cancer J Natl Cancer Inst, February 18, 2004; 96(4): 326 - 331. [Abstract] [Full Text] [PDF]

				L. A. DiFronzo, R. K. Gupta, R. Essner, L. J. Foshag, S. J. O'Day, L. A. Wanek, S. L. Stern, and D. L. Morton Enhanced Humoral Immune Response Correlates With Improved Disease-Free and Overall Survival in American Joint Committee on Cancer Stage II Melanoma Patients Receiving Adjuvant Polyvalent Vaccine J. Clin. Oncol., August 1, 2002; 20(15): 3242 - 3248. [Abstract] [Full Text] [PDF]

				R. Soiffer, T. Lynch, M. Mihm, K. Jung, C. Rhuda, J. C. Schmollinger, F. S. Hodi, L. Liebster, P. Lam, S. Mentzer, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma PNAS, October 27, 1998; 95(22): 13141 - 13146. [Abstract] [Full Text] [PDF]

				S. Osanto Vaccine Trials for the Clinician: Prospects for Tumor Antigens Oncologist, October 1, 1997; 2(5): 284 - 299. [Abstract] [Full Text] [PDF]